TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Neal Ready et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.